98%
921
2 minutes
20
With the advance of genetic technologies, the use of expanded carrier screening (ECS) in the prenatal setting is growing. ECS tests for a wide range of inherited genetic disorders regardless of racial/ethnic background and family history. Latinxs are an important ECS stakeholder group as they are the largest minority group with the highest fertility rate in the United States. Yet, the Latinx population has, to date, been underrepresented and understudied in genetics/genomics research. We conducted a study to explore the knowledge and perspectives of pregnant Latinas regarding ECS in which descriptive statistics and content analysis were used to analyze the data. Thirty-two pregnant Latinas - mostly of low educational levels (no education beyond high school) and with less than $20,000 annual household income living in rural areas were surveyed, provided with education about ECS, and interviewed. Participants were found to possess limited knowledge about ECS prior to being interviewed. Most (68.8%), however, expressed interest in pursuing ECS following the educational component that explained ECS. Their interest was mainly driven by the desire to know their baby's chance of developing a genetic disorder, the low risk of ECS procedures for both pregnant Latinas and their fetus, and the opportunity to better prepare for raising a child with a genetic condition. Our findings contribute to the limited research in the genetics/genomics field by providing in-depth insights into the perspectives of pregnant Latinas regarding ECS. Obstetric providers and genetic counselors should provide culturally appropriate education and counseling to empower pregnant Latinas to make informed decisions about the use of ECS.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jgc4.1696 | DOI Listing |
As the COVID-19 vaccine became available, pregnant people from marginalized communities disproportionately delayed vaccination. Although the urgency of vaccination has subsided, COVID-19 infection during pregnancy continues to pose maternal and fetal risks. Interviews with 45 Latinas residing on the US-Mexico border who were pregnant during the first two years of the pandemic revealed varying degrees of hesitancy related to vaccination during pregnancy.
View Article and Find Full Text PDFJ Lat Psychol
August 2025
New York University, Department of Applied Psychology.
Lingering effects of the COVID-19 pandemic are still of grave concern to families within the U.S. Latine community, as pre-pandemic disparities in healthcare and economic stability were significantly exacerbated by the global crisis (Martínez et al.
View Article and Find Full Text PDFProg Community Health Partnersh
July 2025
Background: Collaborative research between researchers and community members can meaningfully address public health concerns. Collaboration can be complicated, however, due to unanticipated challenges stemming from academic institutions. This article describes how academic institutions can hinder and facilitate community-based research.
View Article and Find Full Text PDFContracept Reprod Med
July 2025
Daré Bioscience Inc, San Diego, CA, USA.
Background: Long-acting injectable (LAI) hormonal contraception offers a promising approach to meet women's pregnancy prevention needs. We sought to understand acceptability of and preferences for LAI hormonal contraception among US women, to optimize the design of a sustained-release LAI in development - including which durations to pursue.
Methods: We implemented a national cross-sectional online survey including a discrete choice experiment (DCE) with women ages 18-44 years currently using or interested in using contraception.
J Endocrinol Invest
July 2025
AME Scientific Committee, Milan, Italy.
Aim: The present guideline (GL) is aimed to improve and standardize the treatment of primary hypothyroidism in non-pregnant adults and to offer all the patients the best possible care across the Italian country.
Target Population: Non-pregnant adults with hypothyroidism.
Excluded Population: This GL does not cover the treatment of hypothyroidism in children and adolescents under 18 years of age, in women who are pregnant or breastfeeding, nor in subjects with central hypothyroidism.